Fig. 5.
Schematic combining systemic dual agonists (STING and TLR4) formulated in immunostimulatory lipid NPs (immuno-NP) with anti-PD1, as a powerful neoadjuvant immunotherapy [119]. Copyright 2009, Royal Society of Chemistry.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.